Eli Lilly and Company $LLY Shares Sold by K.J. Harrison & Partners Inc

K.J. Harrison & Partners Inc lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 13.9% in the second quarter, according to its most recent filing with the SEC. The firm owned 5,582 shares of the company’s stock after selling 898 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in Eli Lilly and Company were worth $4,351,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Ascent Capital Management LLC boosted its position in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after acquiring an additional 12 shares during the period. Willner & Heller LLC boosted its position in Eli Lilly and Company by 1.5% during the 1st quarter. Willner & Heller LLC now owns 854 shares of the company’s stock worth $705,000 after acquiring an additional 13 shares during the period. Braun Bostich & Associates Inc. lifted its holdings in shares of Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after buying an additional 13 shares during the period. Rise Advisors LLC boosted its stake in Eli Lilly and Company by 1.8% during the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after buying an additional 13 shares in the last quarter. Finally, Occidental Asset Management LLC boosted its stake in Eli Lilly and Company by 0.7% during the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after buying an additional 13 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Guggenheim reaffirmed a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 16th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research note on Friday, October 10th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $940.00.

Eli Lilly and Company Trading Up 2.2%

Shares of NYSE LLY opened at $862.96 on Monday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The company has a market cap of $816.75 billion, a price-to-earnings ratio of 56.40, a P/E/G ratio of 1.21 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a fifty day simple moving average of $780.74 and a 200-day simple moving average of $771.97.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.